|
PCR is a Nobel-prize winning technology and it is recognized as one of the most important scientific developments of our
generation. PCR allows scientists to copy a single segment of DNA billions of times, making it possible to take a specimen,
such as a bacterium or virus containing genetic material weighing only one trillionth of a gram, copy its genetic sequence over
and over, and, within hours, generate a test sample sufficient to perform a detailed analysis of a specific genetic question.
Roche Molecular Diagnostics is widely recognized for advances such as thermostable enzymes and the engineering of hot-start
thermostable DNA Polymerases that reduced manual interventions and improved specificity and sensitivity of PCR and real-time
PCR testing.
Ultimately, the company evolved PCR from a highly manual technology to one that combines ease-of-use automation with advances
that enable sample in, results out real-time testing. Most RMD tests come with the added security feature of proprietary Roche-
only AmpErase® enzyme, which, with a closed-tube format, prevents cross-contamination that can lead to
inaccurate test results.
RMD continues to lead innovations through development of real-time PCR, for which the company still holds many active patents.
Now considered the state-of-the-art standard for molecular diagnostics, real-time PCR, greatly improves the sensitivity,
specificity and accuracy of earlier-generation PCR tests.
Using a closed-tube format, real-time PCR, together with AmpErase® enzyme, prevents cross-contamination between samples
being processed in tandem. With its wide dynamic range, a single real-time PCR assay can detect and accurately quantify
as little as a few virus particles up to millions. This capability has enabled important clinical advancements, such as the
highly accurate viral load testing critical to proper assessment of disease progression and response to therapy for HIV and hepatitis.
|
